The renewal of the National Cervical Screening Program

The renewed National Cervical Screening Program (NCSP) will use 5-yearly oncogenic human papillomavirus (HPV) testing and partial genotyping with reflex liquid-based cytology. There is overwhelming evidence from prospective randomised trials that primary HPV screening is vastly superior to cytology testing alone.1,2 The renewal is based on recommendations of the Australian Medical Services Advisory Committee (MSAC) following a robust and transparent process involving a commissioned evidence review and health outcome and economic modelling.3